Celltrion, Inc.
068270
Rang in aandelen
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aandeelprijs
$146.63
Marktkapitalisatie
$33.44B
Verandering (1 dag)
-1.52%
Verandering (1 jaar)
23.60%
Land
KR
Handel Celltrion, Inc. (068270)
Categorie
Healthcare
Winst voor Celltrion, Inc. (068270)
Winst in Jun 2026 TTM: $1.35B
Volgens de meest recente financiële verslagen van Celltrion, Inc. bedraagt de huidige winst van het bedrijf $1.35B. In 2024 behaalde het bedrijf een winst van $391.87M, een daling ten opzichte van de winst van 2023, die $518.41M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Celltrion, Inc. van 2007 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.35B | 69.43% |
| 2025 | $798.62M | 103.80% |
| 2024 | $391.87M | -24.41% |
| 2023 | $518.41M | 4.47% |
| 2022 | $496.21M | -20.13% |
| 2021 | $621.28M | 2.64% |
| 2020 | $605.31M | 82.96% |
| 2019 | $330.83M | 22.13% |
| 2018 | $270.89M | -40.24% |
| 2017 | $453.27M | 138.31% |
| 2016 | $190.20M | 37.04% |
| 2015 | $138.79M | 1.86% |
| 2014 | $136.26M | 24.03% |
| 2013 | $109.86M | -37.65% |
| 2012 | $176.20M | 11.36% |
| 2011 | $158.22M | 61.51% |
| 2010 | $97.97M | 71.21% |
| 2009 | $57.22M | 319.20% |
| 2008 | $13.65M | 4,681.03% |
| 2007 | $285.51K | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 289.84% |
US
|
|
| $-3.09B | -328.14% |
US
|
|
| $-4.02B | -396.82% |
AU
|
|
| $2.85B | 110.31% |
BE
|
|
| $1.95B | 44.16% |
NL
|
